United States Department of State



Washington, D.C. 20520

UNCLASSIFIED

July 15, 2019

ACTION MEMO FOR DEBORAH L. BIRX, AMBASSADOR-AT-LARGE; COORDINATOR OF THE UNITED STATES GOVERNMENT ACTIVITIES TO COMBAT HIV/AIDS AND U.S. SPECIAL REPRESENTATIVE FOR GLOBAL HEALTH DIPLOMACY

SUBJECT: Mozambique Country Operational Plan 2019 Approval

Recommendations

Approve the Mozambique Country Operational Plan (COP) 2019 with a total budget of \$329,948,869, including all initiatives and applied pipeline, to achieve the targets and outcomes as listed in this memo and all appendices. Total budget is reflective of the following programming:

•	New Funding (all accounts)*		Total Budget FY2020 Implementation	
Total Budget	282,228,615	47,720,254	329,948,869	
COP 19 Bilateral	282,228,615	47,720,254	329,948,869	

^{*} New Funding may refer to FY 2019 or other FY appropriations newly allocated for implementation in FY 2020 with COP 2019; accounts indicated in detailed tables.

Approve a total FY 2020 outlay for COP 2019 implementation that does not exceed the total approved COP 2019 budget of \$329,948,869. Any prior year funds that are not included within this COP 2019 budget and documented within this memo, its appendices and official PEPFAR data systems are not to be made available for execution and outlay during FY 2020 without additional written approval. The new FY 2019 funding and prior year funds approved within this memo as a part of the total COP 2019 budget are allocated to achieve specific results, outcomes and impacts as approved. All requested Operational Plan Updates and shifting of funds – either between mechanisms and partners, or to add additional funding to mechanisms and partners for execution in FY 2020 – must be submitted to and approved by S/GAC.

^{**} Pipeline refers to funding allocated in prior years and approved for implementation in FY 2020 with COP

- 2 -

Approved funding will be made available to agency headquarters for allocation to country platform to implement COP 2019 programming and priorities as outlined below and in the appendix.

Approve access for the Mozambique PEPFAR program of up to \$5,191,442 in central funding for the procurement of condoms and lubricants.

Mozambique finalized the COP 2019 plan in Washington, DC in May 2019, under the direction of Embassy Maputo. This plan represents the proposal of the PEPFAR Mozambique team and does not reflect all programmatic recommendations made by S/GAC. It is recognized that the requirements, leadership, and management are overseen by Embassy Maputo, thus performance and execution of the Mozambique PEPFAR program will be monitored, by S/GAC, with these considerations in mind.

Mozambique must fully achieve approved COP 2018 (FY 2019) treatment current (TX_CURR) targets in order to execute the COP 2019 strategy. Suboptimal COP 2018 performance jeopardizes COP 2019 funding and may result in updates to this approval and a decrease to the COP 2019 funding.

Background

This approval is based upon: the discussions that occurred between the country team, agency headquarters, S/GAC, indigenous and international stakeholders and implementing partners in Johannesburg, South Africa during the March 11-15, 2019 in-person planning meetings and the May 29-31, 2019 DC finalization meetings; the final COP 2019 submission, including all data submitted via official PEPFAR systems or within supplemental documents; and Mozambique's in-person COP 2019 approval with Ambassador Birx on May 31, 2019.

Program Summary

Mozambique's Country Operational Plan (COP) 2019 is approved with a revised funding focus and revised targets as designated by the US Ambassador to Mozambique to support PEPFAR Mozambique's vision in partnership with the Government and people of Mozambique to work towards epidemic control by targeting testing to efficiently identify people living with HIV (PLHIV), ensuring all newly diagnosed PLHIV are immediately linked to treatment, and all PLHIV are retained on treatment and remain virally suppressed.


Mozambique will conduct the first Population Based HIV Impact Assessment (PHIA) in FY 2020, so all planning for COP 2019 was done with PEPFAR

- 3 -

program data and estimates from UNAIDS. Programmatic data show that at the end of March 2019, 1,089,714 (49 percent) Mozambicans living with HIV are receiving ART, and 77 percent of those tested are virally suppressed. Viral load coverage remains too low, at 22 percent, leaving 78 percent of Mozambicans without confirmation of viral load suppression for their own health and to decrease transmission. The catastrophically poor retention numbers and low viral load coverage have led to more than 150,081 new infections each year, and unacceptably high mortality rates, the highest for the size of the epidemic. Mozambique now has the second largest HIV epidemic in the world, with the second highest rate of new infections. Mozambique accounts for nearly 10 percent of all global new HIV infections. COP 2019 will work towards achieve epidemic control by the end of FY 2020, across all ages and sexes, focused on 628 health facilities, to maintain 1,841,107 PLHIV on life-saving treatment by the end of FY 2020, while addressing and alleviating the key, systematic and structural barriers to the program's performance.

Over the past few years, PEPFAR Mozambique has shown a rapid increase of positives identified and PLHIV initiated on ART. In COP 2017 and 2018, the PEPFAR Mozambique program data showed sub-optimal and insufficient ability to retain new clients on treatment, which has jeopardized and stalled progress toward country goals for achieving epidemic control. Indeed, by the end of FY 2018, there were fewer clients on treatment than the year prior, despite substantial investments by PEPFAR, due to extremely poor retention and lost to follow-up. A program 'reboot' is needed to draw an immediate focus on retention and address this severe and chronic issue, which results in unacceptably high mortality amidst years of unsuccessful remediation and stalled progress. Mozambique as well as the other "reboot" countries are core contributors to the projected LTFU. Programs and partners needs to evolve programming to both ensure diagnosis and treatment of the sick but also diagnosis, treatment and retention of the well. For nearly 8 years, a person that has HIV will feel well and retention of the well clients will need a different approach. Programming needs to ensure multimonth scripting and immediate access to TLD drug regimens with much lower side effects and a stronger resistance barrier.

- 4 -



PEPFAR Mozambique began this 'reboot' in earnest in January 2019, and demonstrates that long-term retention can be achieved through a more rigorous and tailored monitoring approach, and a tailored response to the barriers clients face at facilities and in the community. A more substantive accountability and action framework agreed to by PEPFAR, the Government of the Republic of Mozambique (GRM) and PEPFAR-funded partners has shown signs of improving critical aspects of HIV care and treatment and addressing barriers identified by defaulters as limiting their willingness to remain in treatment. The PEPFAR Mozambique team conducted more than 160 site visits since January 2019, to identify key bottlenecks to retention and address urgent remediation through in-person and follow-up visits and telephone calls. Since September 2018, at 127 high volume, low retention facilities, the one-month retention rate increased from 63 percent to 81 percent by April 2019, and three-month retention rate increased from 74 percent to 82 percent by April 2019. Work continues to improve these rates further, and this attention to this program area is greatly appreciated.

PEPFAR Mozambique's COP 2019 will use the retention reboot as the foundation for all programming and will complement it with a targeted surge in human resources deployment, and an inclusive civil society-led response to improve 12-month retention to rates that address the mortality and transmission issues that have plagued the national response. Having the appropriate ratio of clinical and lay staff to patients and population at risk of infection is essential to

- 5 -

achieve epidemic control. Over \$70M of COP funding will be directed toward human resource optimization at facility and community levels, to realign existing HRH or fund additional health care workers at the facilities that PEPFAR supports.

An additional part of Mozambique's reboot will be a revamped service delivery package led by the GRM, which includes national adoption of six month drug distribution for stable patients, expansion of TLD to include all men, women, and children by November 2019, and a greater and more cost-efficient direct service support. These policy adoptions will enable Mozambique to stay on pace with its ambitious treatment and viral suppression targets within the 628 facilities that PEPFAR will continue to support in COP 2019, accounting for 90 percent of PLHIV.

In addition to improving retention to enable more patients to maintain ART, in COP 2019, PEPFAR Mozambique will build on the HIV testing "reboot" strategies implemented during COP 2018, which include the rapid introduction of national screening tools to improve the efficiency of provider-initiated counseling and testing (PICT), as well as the repurposing of existing lay counselors to strengthen linkage and early retention follow-up activities. Facility-based index case contact testing will also continue to be expanded into all PEPFAR-supported sites, while community-based index case contact testing will expand in the key catchment areas that represent the largest opportunities to identify positive sexual partners and children of newly diagnosed or symptomatic PLHIV. PEPFAR-support will continue community-based testing among Key Populations (KP) (female sex workers (FSW), men who have sex with men (MSM), and people who inject drugs (PWID)), as well as prisonbased HIV testing in selected districts with PEPFAR-supported health facilities. The program will strengthen use of social media, peer referrals and index case testing, hotspot mapping, and KP-specific screening tools to identify eligible KP for HIV testing. PEPFAR Mozambique will continue to improve linkage rates across all ages and sexes, and to expand same-day HIV treatment enrollment.

PEPFAR Mozambique will offer cervical cancer screening and treatment of preinvasive lesions in concert with ART. Women between 30-49 years should be offered screening every other year with other populations included according to national guidelines. The PEPFAR team should work with GRM to ensure sites are available for referral for diagnosis and treatment of women with suspected invasive cervical cancer.

PEFPAR will continue to aggressively fund HIV prevention activities in Mozambique, including programs for orphans and vulnerable children (OVC), voluntary medical male circumcision, KPs, and Determined, Resilient,

- 6 -

Empowered, AIDS-Free, Mentored, and Safe (DREAMS) services to adolescent girls and young women. The OVC programming will be targeted to the areas of highest unmet need for prevention and treatment services and will especially focus on primary prevention among 9-14 year olds and supporting children and adolescents living with HIV to maintain treatment and viral suppression.

In COP 2019, PEPFAR Mozambique will continue to fund the national level Government to Government (G2G) Cooperative Agreements with the Ministry of Health (MISAU), the National Council to Combat AIDS (CNCS), the National Institute of Health (INS), and agreements with the Provincial Health Directorates (DPS), to provide district level sub-agreements and embedded technical advisors. The focus on these activities will continue to be strengthening the capacity of the national and provincial government actors, to ensure the quality of services provided at health facilities and in institutions meets global standards. The existing agreement with MISAU will be expanded to include additional human resources at over 700 health facilities that PEPFAR will no longer support at the site level. This funding is contingent on the official, written policy of national six month drug dispensation. G2G support to CNCS will strengthen its capacity to coordinate and monitor the multi-sectoral and private sector workplace HIV/AIDS programs, and to ensure quality of community-based services and interventions.

Above site activities in COP 2019 will focus on improving the retention challenges plaguing the Mozambican program, by providing critical support across key areas including human resources for health, community support for HIV prevention and treatment awareness and stigma reduction, laboratory systems, and supply chain strengthening. The determination of activities to continue funding were focused on financial, programmatic, and technical efficiencies that align with programmatic priorities, including differentiated service delivery scale-up, quality improvement and TB preventative therapy (TPT) scale-up.

PEPFAR Mozambique is on track to achieve PEPFAR's thirteen minimum requirements by the end of FY 2019, thanks to recent policy adoption and implementation by the GRM through negotiated agreements during the COP meeting in Johannesburg in March 2019, and during the finalization meeting in Washington, DC, in May 2019. Implementation of many of these policy areas is already underway. As Mozambique moves from adoption to full rollout in the remaining areas, site level management and regular communication with provincial government health teams will be used to ensure fidelity of the implementation at the health facilities throughout the country. This includes targeted testing, differentiated service delivery models and six-month dispensing of prescriptions, and TLD optimization.

Funding Summary

All COP 2019 funding summarized in the chart below is approved at the agency and account levels as indicated. Funds are to be utilized to achieve the targets and outcomes and to fund implementing partners and Management and Operations costs (U.S. Government Costs of Doing Business) as documented in all PEPFAR systems and summarized in the appendix.

	FY 2019 I	FY 2019 New		Analisal Dinalina*	Total COP 19 Bilateral	
Mozambique	GHP-State	GAP	Total New Funds	Applied Pipeline*	Budget	
DOD TOTAL	8,141,276	-	8,141,276	272,510	8,413,786	
of which, Acceleration	354,071	-	354,071	-	354,071	
of which, Cervical cancer	100,000	-	100,000	-	100,000	
of which, VMMC	2,901,281	-	2,901,281	-	2,901,283	
HHS TOTAL	106,208,965	3,075,000	109,283,965	45,070,933	154,354,898	
HHS/CDC	103,898,201	3,075,000	106,973,201	44,931,697	151,904,898	
of which, Acceleration	7,140,442	-	7,140,442	-	7,140,44	
of which, Cervical cancer	3,514,670	-	3,514,670	-	3,514,67	
of which, DREAMS	3,760,058	-	3,760,058	183,892	3,943,95	
of which, VMMC	9,001,154	-	9,001,154	12,746,424	21,747,578	
HHS/HRSA	2,310,764	-	2,310,764	139,236	2,450,00	
of which, VMMC	200,000	-	200,000	=	200,000	
PEACE CORPS TOTAL	2,116,397	-	2,116,397	1,104,666	3,221,06	
STATE TOTAL	2,799,028	-	2,799,028	-	2,799,02	
State	2,026,028	-	2,026,028	-	2,026,02	
State/AF	773,000	-	773,000	-	773,000	
USAID TOTAL	159,887,949	-	159,887,949	1,272,145	161,160,094	
USAID, non-WCF	93,263,323	-	93,263,323	1,272,145	94,535,468	
of which, Acceleration	5,735,373	-	5,735,373	=	5,735,37	
of which, Cervical cancer	1,412,149	-	1,412,149	-	1,412,14	
of which, DREAMS	5,976,820	-	5,976,820	275,000	6,251,82	
of which, USAID LES	922,051	-	922,051	-	922,05	
of which, VMMC	10,386,972	-	10,386,972	153,836	10,540,808	
USAID, WCF	66,624,626	-	66,624,626	-	66,624,626	
of which, Acceleration	770,114	-	770,114	-	770,114	
of which, VMMC	4,440,522	-	4,440,522	-	4,440,52	
TOTAL	279,153,615	3,075,000	282,228,615	47,720,254	329,948,869	
of which, Acceleration	14,000,000	-	14,000,000	-	14,000,000	
of which, Cervical cancer	5,026,819	-	5,026,819	-	5,026,81	
of which, DREAMS	9,736,878	-	9,736,878	458,892	10,195,770	
of which, USAID LES	922,051	-	922,051	-	922,05	
of which, VMMC	26,929,929	-	26,929,929	12,900,260	39,830,189	

st Pipeline refers to funding allocated in prior years, approved for implementation in FY 2020

GHP-State Funds: Upon the clearance of a FY 2019 PEPFAR GHP-State Congressional Notification (CN), funds will be made available for transfer to agency HQs as indicated in the above chart. Funds are made available for outlay in FY 2020 at approved COP 2019 partner budget levels to achieve FY 2020 targets and outcomes as documented in official PEPFAR systems and summarized in the approval memo's appendix. Upon receipt from S/GAC, agency headquarters will move the funds to the country platform via each agency's internal process.

CDC GAP Funds: With the receipt of this signed memo, CDC is approved to use CDC GAP funds, as indicated in the above funding chart. Funds are to be made available for outlay in FY 2020 at approved COP 2019 partner budget levels to achieve FY 2020 targets and outcomes as documented in official PEPFAR systems and summarized in the approval memo's appendix. With this

- 8 -

approval, CDC GAP funding may be made available to country teams per CDC internal processes and following agency requirements.

Applied Pipeline Funds: With the receipt of this signed memo, respective agencies are approved to use applied pipeline funds as indicated in the above funding chart. Funds are to be made available for outlay in FY 2020 at approved COP 2019 partner budget levels to achieve FY 2020 targets and outcomes as documented in official PEPFAR systems and summarized in the approval memo's appendix. Additional or remaining pipeline from previous year's activities that are not currently captured in the COP 2019 total budget level and documented within COP 2019 partner budgets are not to be executed our outlayed without written approval from the Global AIDS Coordinator.

FY 2020 Target Summary

FY 2019 funds are released and COP 2019 applied pipeline is approved to achieve the following results in FY 2020.

- 9 -

HTS_INDEX					SNU Prioriti	zations		
HTS_INDEX	Mozambique			Scale-Up:	Scale-Up:		Centrally	
HTS_INDEX Total Total 405,898 HTS_TST 15+ 15- 15- 15- 15- 15- 15- 15-			Attained	Saturation	Aggressive	Sustained	Supported	Total *
Total 89,541 121,842 907,724 - 170 1 HTS_TST 15+ 319,939 475,510 4,917,715 149,941 5 Total 408,989 615,024 6,226,276 - 157,806 7 Total 408,989 615,024 6,226,276 - 157,806 7 HTS_TST_POS 15+ 39,661 58,707 526,385 7,615 Total 42,774 63,277 567,256 - 7,816 Total 41,778 60,779 526,385 7,615 TX_NEW 15+ 37,748 55,712 503,377 3,983 TX_NEW 15+ 37,748 55,712 503,377 3,983 TX_NEW 15+ 99,567 147,200 1,389,744 35,905 1 TX_CURR 15+ 99,567 147,200 1,389,744 35,905 1 TX_CURR 15+ 99,567 147,200 1,389,744 35,905 1 TX_PVIS 15+ 47,786 7,075 67,646 2,038 TX_PVIS 15+ 56,486 83,551 797,401 22,777 Total 61,272 90,626 865,047 25,815 1 CXCA_SCRN Total (15+) 18,298 27,048 162,436 1,228 OVC_SERV 18+ 1,653 4,003 49,844 - 10,665 1,720 OVC_HIVSTAT Total (15) 12,712 30,790 379,487 0 OVC_HIVSTAT Total (15) 12,712 30,790 379,487 0 OVC_HIVSTAT Total 43,048 51,664 1,273,875 141,561 1 PMICT_STAT_POS 15+ 4,491 5,773 125,164 13,391 PMICT_STAT_POS 15+ 4,491 5,773 125,164 13,391 PMICT_STAT Total 4,520 5,802 126,009 13,537 PMICT_STAT Total 1,54 4,991 5,773 125,164 13,391 PMICT_STAT Total 4,520 5,802 126,009 13,537 PMICT_STAT Total 1,54 4,991 5,773 125,164 13,391 PMICT_STAT Total 4,520 5,802 126,009 13,537 PMICT_STAT Total 1,54 5,56 5 13,871 47,119 0 PMICT_STAT Total 5,50 5 13,871 47,119 0 PMICT_STAT Total 5,50 5 13,871 47,119 0 PMICT_STAT Total 4,520 5,802 126,009 13,537 PMICT_STAT Total 5,50 7,50 13,87 141,561 1 PMICT_STAT Total 5,50 7,50 13,871 47,119 0 PMICT_STAT 15+ 4,472 5,50 3,38 5,50 7 - 0 PMICT_STAT 15+ 4,471 5,50 7,73 125,164 13,391 17 PMICT_STAT 15+ 4,491 5,773 1		<15	26,736	39,513	305,634		62	372,6
HTS_IST	HTS_INDEX	15+	53,805	82,329	602,090		108	748,1
HTS_TST		Total	80,541	121,842	907,724	-	170	1,120,7
Total		<15	89,050	139,514	1,308,561		7,865	1,566,2
HTS_TST_POS	HTS_TST	15+	319,939	475,510	4,917,715		149,941	5,934,5
HTS_TST_POS		Total	408,989	615,024	6,226,276	-	157,806	7,500,8
Total 42,774 63,277 567,256 7,816		<15	3,113	4,570	40,871		201	49,:
Total	HTS TST POS	15+	39,661	58,707	526,385		7,615	637,
TX_NEW		Total	42,774	63,277	567,256	-	7,816	686,
Total		<15	3,430	5,037	45,825		473	55,
Total	TX NEW	15+			502,377		3,983	605,
TX_CURR 15+ 99,567 147,200 1,389,744 35,905 1 Total 107,835 149,400 1,589,666 - 38,883 1 TX_PVLS 15+ 4,786 7,075 67,646 2,038 TX_PVLS 15+ 56,486 83,551 797,401 23,777 Total 61,272 90,626 865,047 - 25,815 1 CXCA_SCRN Total (15+) 18,298 27,048 162,436 1,228 □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	-					_		660,
TX_CURR Total Total 107,835 159,410 1,505,066 - 38,883 TX_PVLS 155 4,786 7,075 56,646 2,038 TX_PVLS 15+ 56,486 83,551 797,401 23,777 Total 61,272 90,626 865,047 - 25,815 1 CXCA_SCRN Total (15+) 18,298 27,048 162,436 1,228 OVC_SERV 18+ 1,653 4,003 49,844 - Total 12,712 30,790 379,487 - Total OVC_HIVSTAT Total (148) 11,059 26,787 329,633 - Total OVC_HIVSTAT Total (148) 11,059 26,792 329,639 - Total 15+ 42,723 51,350 1,263,210 139,841 1 PMTCT_STAT 15+ 42,723 51,350 1,263,210 139,841 1 Total 43,048 51,664 1,773,875 - 141,561 1 PMTCT_STAT_POS 15+ 4,491 5,773 125,164 13,391 Total 4,520 5,802 126,009 - 13,537 PMTCT_EID Total 4,520 5,803 8,038 31,581 - PP_PREV 15+ 15+ 15+ 15+ 15+ 15+ 15+ 15					·		•	139,
Total 107,835 159,410 1,505,066 - 38,883 1 TX PVLS 15+ 4,786 7,075 67,646 2,038 TX PVLS 15+ 56,486 7,075 67,646 2,038 TX PVLS 15+ 56,486 83,551 797,401 23,777 Total 61,272 90,626 865,047 - 25,815 1 CXCA_SCRN Total (15+) 18,298 27,048 162,436 1,228 □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	TX CLIRR							1,691,
TX_PVLS	TX_COMM					_		1,831,
TX_PVLS			•	•				84,
CXCA_SCRN Total (15+) 18,298 27,048 162,436 1,228 OVC_SERV 18+ 1,653 4,003 49,844 - OVC_SERV 18+ 1,653 4,003 49,844 - OVC_HIVSTAT Total 12,712 30,790 379,487 - OVC_HIVSTAT Total (<18)	TV DV/IC			-	· · · · · · · · · · · · · · · · · · ·			973,
CXCA_SCRN Total (15+) 18,298 27,048 162,436 1,228 OVC_SERV 18+ 11,059 26,787 329,643 - OVC_SERV 18+ 1,653 4,003 49,844 - OVC_HIVSTAT Total (<18)	IX_PVLS							
OVC_SERV		-	•	-	•	-	-	1,057,
OVC_SERV 18+ 1,653 4,003 49,844 - OVC_HIVSTAT Total (s18) 12,712 30,790 379,487 - OVC_HIVSTAT Total (s18) 11,059 26,792 329639 - PMTCT_STAT 15+ 42,723 51,350 1,263,210 139,841 1 Total 43,048 51,664 1,273,875 - 141,561 1 PMTCT_STAT_POS 15+ 4,491 5,773 125,164 13,391 Total 4,520 5,802 126,009 - 13,537 PMTCT_ART 15+ 4,491 5,773 125,164 13,391 PMTCT_EID Total 4,520 5,802 126,009 - 13,537 PMTCT_EID Total 4,327 5,603 85,407 - - PP_PREV 15+ 565 13,871 47,218 - - PMP_PREV Total 1,	CXCA_SCRN	<u> </u>			·		1,228	210,
Total 12,712 30,790 379,487 -							-	367,
OVC_HIVSTAT Total (<18) 11,059 26,792 329,639 - PMTCT_STAT <15	OVC_SERV				•		-	55,
PMTCT_STAT			12,712	30,790	379,487	-	-	422,
PMTCT_STAT	OVC_HIVSTAT	Total (<18)	11,059	26,792	329,639		-	367,
Total		<15	325	314	10,665		1,720	13,
CAMICT_STAT_POS	PMTCT_STAT	15+	42,723	51,350	1,263,210		139,841	1,500,
CAMICT_STAT_POS		Total	43,048	51,664	1,273,875	-	141,561	1,513,
Total		<15	29	29	845		146	1,
Total	PMTCT STAT POS	15+	4,491	5,773	125,164		13,391	149,
MICT_ART 15+		Total				-		150,
PMTCT_ART								1,
Total 4,520 5,802 126,009 - 13,537 PMTCT_EID Total 4,367 5,603 85,407 - <15	PMTCT ART		-	-				148,
PMTCT_EID					•	-		150,
PP_PREV	PMTCT_FID		· · · · · · · · · · · · · · · · · · ·	•	•		-	95,
PP_PREV 15+ 565 13,871 47,218 - KP_PREV Total 1,816 4,214 28,438 - KP_MAT Total - - - VMMC_CIRC 15+ 1,959 11,184 125,443 - VMMC_CIRC 15+ 11,325 18,455 199,510 - Total 13,284 29,639 324,953 - - HTS_SELF Total - - - - - PrEP_NEW Total 712 1,140 6,571 91 91 PrEP_CURR Total 843 1,193 8,154 17 TB_STAT (N) 15+ 4,733 6,248 73,625 - Total 5,225 7,058 83,072 - TB_ART (N) 15+ 2,200 2,873 34,021 - Total 2,412 3,195 37,958 - TB_PREV (N) 15+	T WITCI_LID			•	•		_	40,
Total 645 21,909 78,799 - - KP_PREV Total 1,816 4,214 28,438 - KP_MAT Total - - - VMMC_CIRC 15+ 11,959 11,184 125,443 - VMMC_CIRC 15+ 11,325 18,455 199,510 - Total 13,284 29,639 324,953 - - HTS_SELF Total -	DD DDE\/				· · · · · · · · · · · · · · · · · · ·		_	84,
KP_PREV Total 1,816 4,214 28,438 - KP_MAT Total - - - - VMMC_CIRC 15+ 1,959 11,184 125,443 - VMMC_CIRC 15+ 11,325 18,455 199,510 - Total 13,284 29,639 324,953 - - HTS_SELF Total -	FF_FILL							124,
KP_MAT Total -	KD DDEM			•	•		_	34,
VMMC_CIRC 415 1,959 11,184 125,443 - VMMC_CIRC 15+ 11,325 18,455 199,510 - Total 13,284 29,639 324,953 - - HTS_SELF Total - - - - PrEP_NEW Total 712 1,140 6,571 91 PrEP_CURR Total 843 1,193 8,154 17 TB_STAT (N) 15+ 492 810 9,447 - Total 5,225 7,058 83,072 - Total 5,225 7,058 83,072 - TB_ART (N) 15+ 2,200 2,873 34,021 - Total 2,412 3,195 37,958 - - TB_PREV (N) 15+ 30,525 44,805 397,452 - - Total 30,789 45,192 400,890 - <	_		1,010	4,214	20,430		-	34,
VMMC_CIRC 15+ 11,325 18,455 199,510 - Total 13,284 29,639 324,953 - - HTS_SELF Total - - - - PrEP_NEW Total 712 1,140 6,571 91 PrEP_CURR Total 843 1,193 8,154 17 FEP_CURR Total 492 810 9,447 - TB_STAT (N) 15+ 4,733 6,248 73,625 - Total 5,225 7,058 83,072 - - TB_ART (N) 15+ 2,200 2,873 34,021 - TOTAL 2,412 3,195 37,958 - - TB_PREV (N) 15+ 30,525 44,805 397,452 - - Total 30,789 45,192 400,890 - - TX_TB (N) 15+ 99,573 146,951 1,317,568 - 1 </td <td>KP_IVIAT</td> <td></td> <td>1.000</td> <td>11 104</td> <td>125 442</td> <td></td> <td>-</td> <td>155</td>	KP_IVIAT		1.000	11 104	125 442		-	155
Total 13,284 29,639 324,953 - - HTS_SELF Total - - - - - PrEP_NEW Total 712 1,140 6,571 91 PrEP_CURR Total 843 1,193 8,154 17 TB_STAT (N) 15+ 492 810 9,447 - TB_STAT (N) 15+ 4,733 6,248 73,625 - Total 5,225 7,058 83,072 - - TB_ART (N) 15+ 2,200 2,873 34,021 - TB_ART (N) 15+ 2,200 2,873 34,021 - TOTAL 2,412 3,195 37,958 - - TB_PREV (N) 15+ 30,525 44,805 397,452 - - Total 30,789 45,192 400,890 - - TX_TB (N) 15+ 99,573 146,951 1,317,568 -	VANAC CIDC			-	· · · · · · · · · · · · · · · · · · ·			155,
HTS_SELF Total - <t< td=""><td rowspan="2"></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td>249,</td></t<>							-	249,
PrEP_NEW Total 712 1,140 6,571 91 PrEP_CURR Total 843 1,193 8,154 17 TB_STAT (N) 15+ 492 810 9,447 - TB_STAT (N) 15+ 4,733 6,248 73,625 - Total 5,225 7,058 83,072 - - TB_ART (N) 15+ 2,200 2,873 34,021 - TOTAL 2,412 3,195 37,958 - - TB_PREV (N) 15+ 30,525 44,805 397,452 - - TOTAL 30,789 45,192 400,890 - - - TX_TB (N) 15+ 99,573 146,951 1,317,568 - 1			13,284	29,639	324,953	-	-	405,
PrEP_CURR Total 843 1,193 8,154 17 TB_STAT (N) 415 492 810 9,447 - TB_STAT (N) 15+ 4,733 6,248 73,625 - Total 5,225 7,058 83,072 - - TB_ART (N) 15+ 2,200 2,873 34,021 - Total 2,412 3,195 37,958 - - TB_PREV (N) 15+ 30,525 44,805 397,452 - - Total 30,789 45,192 400,890 - - - TX_TB (N) 15+ 99,573 146,951 1,317,568 - 1			-		-	-		
TB_STAT (N) 15+ 4,733 6,248 73,625 - Total 5,225 7,058 83,072 -				•				8,
TB_STAT (N) 15+ 4,733 6,248 73,625 - Total 5,225 7,058 83,072 - - 415 212 322 3,937 - TB_ART (N) 15+ 2,200 2,873 34,021 - Total 2,412 3,195 37,958 - - 415 264 387 3,438 - - TB_PREV (N) 15+ 30,525 44,805 397,452 - - Total 30,789 45,192 400,890 - - <15	PrEP_CURR			· .	•			10,
Total 5,225 7,058 83,072 - - TB_ART (N) 15+ 212 322 3,937 - TB_ART (N) 15+ 2,200 2,873 34,021 - Total 2,412 3,195 37,958 - - TB_PREV (N) 15+ 30,525 44,805 397,452 - Total 30,789 45,192 400,890 - - TX_TB (N) 15+ 99,573 146,951 1,317,568 - 1	TB_STAT (N)						-	10,
TB_ART (N) 415 212 322 3,937 - TB_ART (N) 15+ 2,200 2,873 34,021 - Total 2,412 3,195 37,958 - - 415 264 387 3,438 - TB_PREV (N) 15+ 30,525 44,805 397,452 - Total 30,789 45,192 400,890 - - 415 8,396 12,309 110,992 - TX_TB (N) 15+ 99,573 146,951 1,317,568 - 1							-	85,
TB_ART (N) 15+ 2,200 2,873 34,021 - Total 2,412 3,195 37,958 - - 415 264 387 3,438 - TB_PREV (N) 15+ 30,525 44,805 397,452 - Total 30,789 45,192 400,890 - - <15			•			-	-	96,
Total 2,412 3,195 37,958 - - <15							-	4,
TB_PREV (N) 415 264 387 3,438 - TB_PREV (N) 15+ 30,525 44,805 397,452 - Total 30,789 45,192 400,890 - - <15	TB_ART (N)	15+	2,200				-	39,
TB_PREV (N) 15+ 30,525 44,805 397,452 - Total 30,789 45,192 400,890 - - <15		Total	2,412	3,195	37,958		-	44,
Total 30,789 45,192 400,890 - - <15		<15	264	387	3,438		-	4,
Total 30,789 45,192 400,890 - - <15	TB_PREV (N)	15+	30,525	44,805			-	478,
<15						-	-	482,
TX_TB (N) 15+ 99,573 146,951 1,317,568 - 1	TX_TB (N)				•		-	133,
- ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '							-	1,584,
		Total	107,969	159,260	1,428,560	-	_	1,717,
GEND GBV Total 4,567 4,245 36,563 -	GEND GBV							45,

- 10 -

Budgetary Requirements

Mozambique has programmed FY 2019 funding in support of required earmarks as follows:

·	FY 2019 COP19 Funding
Earmarks	Level*
Care & Treatment	182,177,828
HKID Requirement	13,596,486
Preventing and Responding to Gender-based Violence	3,287,967
Water	600,000
* Does not include central funds	

Partner Management and Stakeholder Engagement

Agreements made during COP discussions, including those regarding geographic focus, targets, budgets, SIMS, use of pipeline, partner implementation and partner management will be monitored and evaluated on a regular basis via both ad hoc check-ins and discussions as well as the joint HQ and country team POART discussions. It is expected that teams closely monitor partner performance and engage with each implementing partner on a regular basis to ensure achievement of targets, outcomes and impact in a manner consistent with the this memo, approved SDS, and budgets and targets as finalized in PEPFAR systems. Any partner found not to be on track to achieve 80% of its approved targets or outcomes by the end of the second quarter must be placed on an improvement plan with clear benchmarks to measure improvement. The country team should notify the S/GAC Chair and PPM immediately of the improvement plan.

Continued engagement with all stakeholders, including civil society and community members, multilateral partners and bilateral partners, is to continue throughout COP implementation. Core to this critical engagement is the sharing of and discussion surrounding quarterly results and achievement. This continued engagement will ensure all parties' understanding of Mozambique's progress and help identify any strategic changes to be made in order to more efficiently and effectively reach epidemic control.